The current financial score of Amneal Pharmaceuticals Inc is 7.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 862.68M, representing a year-over-year increase of 9.96%, while its net profit experienced a year-over-year increase of 1015.79%.
The current valuation score of Amneal Pharmaceuticals Inc is 8.23. Its current P/E ratio is 50.16, which is 1924.17% below the recent high of 1015.40 and 911.17% above the recent low of -406.91.
The current earnings forecast score of Amneal Pharmaceuticals Inc is 8.86. The average price target is 23.91, with a high of 27.00 and a low of 20.00.
The current price momentum score of Amneal Pharmaceuticals Inc is 3.34. Currently, the stock price is trading between the resistance level at 21.16 and the support level at 18.26, making it suitable for range-bound swing trading.
The current institutional shareholding score of Amneal Pharmaceuticals Inc is 5.00. The latest institutional shareholding proportion is 50.67%, representing a quarter-over-quarter decrease of 8.96%.
The current risk assessment score of Amneal Pharmaceuticals Inc is 7.63. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.